Dr. Farrell C. Tyson II, MD

Dr. Tyson practices at Tyson Eye Care in Naples, Florida.

Dr. Tyson's NPI, 1508857491, was assigned on October 31, 2005. Dr. Tyson graduated from USF Health Morsani College of Medicine in 1997. Dr. Tyson holds Florida license ME81910.

Dr. Tyson's primary practice is Tyson Eye Care, at 2640 Golden Gate Pkwy, Naples, FL 34105 in Collier County. The practice phone is (239) 542-2020.

Dr. Tyson's primary practice is Tyson Eye Care in Naples, Florida. Dmand AI also links Dr. Tyson to 2 medical groups, 1 group practice or clinic and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tyson practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Tyson's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Tyson is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Tyson's licenses on file in 2 states: Florida and South Carolina.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. Tyson treats.

CMS data shows 3,540 Medicare services from Dr. Tyson across 15 procedure codes in 2024, for 1,061 Medicare patients. Medicare paid $573,502 for them.

CMS counts 1,061 Medicare patients who saw Dr. Tyson in 2024. The largest group is 65 to 74, with 533 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 2% are also on Medicaid. Their average risk score is 1.03, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Tyson's median patient age at 73, with 54% women.

In 2024, Dr. Tyson wrote 396 Medicare Part D claims for 125 patients. 62% of them were for generic drugs. CMS names the drug for 275 of them, across 6 drugs with 11 or more claims each, at $21,397 in total drug cost. In 2023, CMS named 259 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Tyson for performance year 2024, reported individually. Dr. Tyson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 1,490 procedures of cataract surgery by Dr. Tyson, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 6 papers to Dr. Tyson, published from 2014 to 2025. 2025 was the busiest year, with 2. The most frequent topics are Visual Acuity, Cataract and Cataract Extraction. Dr. Tyson has published most often in J Cataract Refract Surg. Dr. Tyson's most frequent co-authors are David F. Chang, MD, William Montgomery Flynn, MD and William John Flynn, MD, OD.

Dmand AI links Dr. Tyson to 7 clinical trials. Conditions studied include Lens Diseases, Cataract and Aphakia. Glaukos Corporation sponsors the most, 2. Open Payments lists research payments to Dr. Tyson that name 1 trial.

CMS Open Payments shows 829 general payments to Dr. Tyson from 42 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 71% of the total. Carl Zeiss Meditec, Inc. paid the most, $1,742,820. It also lists 7 research payments totaling $98,930 from 2016 to 2019, naming 1 clinical trial.

Dmand AI lists 2 awards for Dr. Tyson.

Dr. Tyson graduated from USF Health Morsani College of Medicine in 1997. Dr. Tyson is a member of AAO, ACS, ASCRS, Society for Excellence in Eyecare and Windsor National Associates.

Dr. Tyson is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.